Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics

Abstract Background and Aims To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide. Methods and results A multi-centre, open-label, randomized, and active-comparator trial. Patients were randomized to dapagliflozin 10 mg once daily or metolazone 5–10 mg once daily for a 3-day treatment period, with follow-up for primary and secondary endpoints until day 5 (96 h). The primary endpoint was a diuretic effect, assessed by change in weight (kg). Secondary endpoints included a change in pulmonary congestion (lung ultrasound), loop diuretic efficiency (weight change per 40 mg of furosemide), and a volume assessment score. 61 patients were randomized. The mean (±standard deviation) cumulative dose of furosemide at 96 h was 977 (±492) mg in the dapagliflozin group and 704 (±428) mg in patients assigned to metolazone. The mean (±standard deviation) decrease in weight at 96 h was 3.0 (2.5) kg with dapagliflozin compared to 3.6 (2.0) kg with metolazone [mean difference 0.65, 95% confidence interval (CI) −0.12,1.41 kg; P = 0.11]. Loop diuretic efficiency was less with dapagliflozin than with metolazone [mean 0.15 (0.12) vs. 0.25 (0.19); difference −0.08, 95% CI −0.17,0.01 kg; P = 0.10]. Changes in pulmonary congestion and volume assessment score were similar between treatments. Decreases in plasma sodium and potassium and increases in urea and creatinine were smaller with dapagliflozin than with metolazone. Serious adverse events were similar between treatments. Conclusion In patients with heart failure and loop diuretic resistance, dapagliflozin was not more effective at relieving congestion than metolazone. Patients assigned to dapagliflozin received a larger cumulative dose of furosemide but experienced less biochemical upset than those assigned to metolazone. Trial registration ClinicalTrials.gov Identifier: NCT04860011

[1]  G. Filippatos,et al.  Sodium and potassium changes during decongestion with acetazolamide – A pre‐specified analysis from the ADVOR trial , 2023, European journal of heart failure.

[2]  F. Formiga,et al.  Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. , 2022, European heart journal.

[3]  G. Filippatos,et al.  Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial , 2022, Circulation.

[4]  C. Angermann,et al.  Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial , 2022, European heart journal.

[5]  G. Filippatos,et al.  Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. , 2022, The New England journal of medicine.

[6]  Akshay S. Desai,et al.  SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials , 2022, The Lancet.

[7]  G. Sinagra,et al.  [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: what's new?] , 2022, Giornale italiano di cardiologia.

[8]  J. Cleland,et al.  Worsening renal function in acute heart failure in the context of diuretic response , 2021, European journal of heart failure.

[9]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[10]  B. Pitt,et al.  Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure. , 2020, Hypertension.

[11]  G. Felker,et al.  Diuretic Therapy for Patients With Heart Failure: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[12]  C. Wilcox Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors , 2020, Hypertension.

[13]  S. Solomon,et al.  Quantification of pleural effusions on thoracic ultrasound in acute heart failure , 2020, European heart journal. Acute cardiovascular care.

[14]  H. Heerspink,et al.  Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF) , 2020, European journal of heart failure.

[15]  D. Lenihan,et al.  Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial. , 2019, JACC. Heart failure.

[16]  S. Solomon,et al.  Lung Ultrasound in Acute Heart Failure: Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes. , 2019, JACC. Heart failure.

[17]  J. Testani,et al.  Loop diuretic resistance complicating acute heart failure , 2019, Heart Failure Reviews.

[18]  M. Vaduganathan,et al.  Spironolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. , 2019, The Canadian journal of cardiology.

[19]  G. Filippatos,et al.  The use of diuretics in heart failure with congestion — a position statement from the Heart Failure Association of the European Society of Cardiology , 2019, European journal of heart failure.

[20]  J. McMurray,et al.  Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis , 2018, Diabetes, obesity & metabolism.

[21]  J. Massaro,et al.  Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload. , 2017, Journal of the American College of Cardiology.

[22]  Adrian F Hernandez,et al.  Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. , 2013, JAMA.

[23]  K. Anstrom,et al.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome. , 2012, The New England journal of medicine.

[24]  M. Metra,et al.  Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure?: The Role of Congestion and Its Interaction With Renal Function , 2012, Circulation. Heart failure.

[25]  Adrian F Hernandez,et al.  Diuretic strategies in patients with acute decompensated heart failure. , 2011, The New England journal of medicine.

[26]  K. Swedberg,et al.  Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.

[27]  M. Guglin,et al.  Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. , 2007, Journal of the American College of Cardiology.

[28]  S. Iyengar,et al.  Diuretic resistance in heart failure , 2006, Current heart failure reports.

[29]  W. Suki DIURETIC RESISTANCE? , 1979, The Lancet.

[30]  T. Walles,et al.  Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart , 2014, Pflügers Archiv - European Journal of Physiology.